{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LCZ+696&page=2",
    "query": {
      "intervention": "LCZ 696",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=LCZ+696&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T20:54:26.319Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03988634",
      "title": "Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction (HFpEF)"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        },
        {
          "name": "valsartan",
          "type": "DRUG"
        },
        {
          "name": "sacubitril/valsartan matching placebo",
          "type": "DRUG"
        },
        {
          "name": "valsartan matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 467,
      "start_date": "2019-06-29",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 87,
      "location_summary": "Irvine, California • Long Beach, California • Los Angeles, California + 77 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03988634"
    },
    {
      "nct_id": "NCT05168787",
      "title": "Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "sacubitril/valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Methodist Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6558,
      "start_date": "2020-08-13",
      "completion_date": "2025-07-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05168787"
    },
    {
      "nct_id": "NCT03738878",
      "title": "Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "LCZ696",
          "type": "DRUG"
        },
        {
          "name": "Bradykinin",
          "type": "DRUG"
        },
        {
          "name": "Substance P",
          "type": "DRUG"
        },
        {
          "name": "BNP",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 4,
      "start_date": "2018-11-15",
      "completion_date": "2024-12-01",
      "has_results": true,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03738878"
    },
    {
      "nct_id": "NCT02924727",
      "title": "Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "LCZ696 (sacubitril/valsartan)",
          "type": "DRUG"
        },
        {
          "name": "Ramipril",
          "type": "DRUG"
        },
        {
          "name": "Placebo of LCZ696",
          "type": "DRUG"
        },
        {
          "name": "Placebo of ramipril",
          "type": "DRUG"
        },
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "Placebo of valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5669,
      "start_date": "2016-12-09",
      "completion_date": "2021-02-26",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02924727"
    },
    {
      "nct_id": "NCT04736433",
      "title": "Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "ACE inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Sacubitril/Valsartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6066,
      "start_date": "2020-09-22",
      "completion_date": "2021-02-18",
      "has_results": false,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04736433"
    },
    {
      "nct_id": "NCT04055428",
      "title": "NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Cardiovascular Diseases",
        "Insulin Sensitivity/Resistance",
        "Metabolic Disease",
        "Natriuretic Peptides",
        "Metabolism",
        "Energy Expenditure"
      ],
      "interventions": [
        {
          "name": "Sacubitril, Valsartan 97-103 mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 160 mg",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Glucose Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "Standardized Meals",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Exercise capacity VO2 maximum determination",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2020-08-15",
      "completion_date": "2027-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04055428"
    },
    {
      "nct_id": "NCT04113109",
      "title": "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "LCZ 696",
          "type": "DRUG"
        },
        {
          "name": "Icatibant",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Para-aminohippurate",
          "type": "DRUG"
        },
        {
          "name": "Iohexol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2019-11-01",
      "completion_date": "2025-07-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04113109"
    },
    {
      "nct_id": "NCT01681576",
      "title": "Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Salt-sensitive Hypertension"
      ],
      "interventions": [
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "LCZ696",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2012-08",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2015-11-10",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Cypress, California • Glendale, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01681576"
    },
    {
      "nct_id": "NCT01922089",
      "title": "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "LCZ696",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 498,
      "start_date": "2013-11",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2015-10-15",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 22,
      "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 18 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01922089"
    },
    {
      "nct_id": "NCT02636283",
      "title": "Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral Arterial Disease"
      ],
      "interventions": [
        {
          "name": "Entresto",
          "type": "DRUG"
        },
        {
          "name": "Placebo group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 6,
      "start_date": "2017-12-31",
      "completion_date": "2018-11-01",
      "has_results": true,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-09-23T20:54:26.319Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02636283"
    }
  ]
}